Guangdong Taiantang Pharmaceutical Co Ltd operates within the Pharmaceutical preparations sector.
In addition to historical fundamental analyses, the complete report available to purchase compares Guangdong Taiantang Pharmaceutical Co Ltd with three other
companies in this sector in CHINA :
Haisco Pharmaceutical Group Co Ltd
sales of 3.94 billion Chinese Renmimbi [US$562.33 million]
of which 100%
was Pharmaceutical Industry),
SSY Group Ltd
(4.08 billion Chinese Renmimbi [US$583.09 million]
of which 97%
was Intravenous Infusion Solution and Others), and
Cisen Pharmaceutical Co Ltd
(4.11 billion Chinese Renmimbi [US$586.78 million]
of which 96%
was Pharmaceutical manufacture).
During the year ended December of 2019, sales at
Guangdong Taiantang Pharmaceutical Co Ltd were 4.01 billion Chinese Renmimbi (US$573.14 million).
increase of 21.1%
versus 2018, when the company's sales were 3.31 billion Chinese Renmimbi.
This was the fifth consecutive year of sales increases at Guangdong Taiantang Pharmaceutical Co Ltd
(and since 2014, sales have increased a total of 227%).
Sales of Medicine Wholesale and Retail saw an increase
40.1% in 2019, from
2.33 billion Chinese Renmimbi to 3.26 billion Chinese Renmimbi.
Not all segments of Guangdong Taiantang Pharmaceutical Co Ltd experienced an increase in sales in 2019:
sales of Health Industry Development Products Sale fell 59.6% to 55.67 million Chinese Renmimbi.
(However, this segment's sales were only a very small portion of the company's overall sales).
Guangdong Taiantang Pharmaceutical Co Ltd also experienced decreases in sales in
Chinese Herbal Medicine Pre-Processing (down 29.5% to 468.17 million Chinese Renmimbi)